Skip to main content
. 2023 Jan 12;14:1–13. doi: 10.18632/oncotarget.28341

Figure 3. STRO-001 showed potent cell killing activity on proliferating primary human B cells.

Figure 3

(A) In vitro expanded primary B cells showed increased CD86, HLA-DR and CD74 expression compared to naïve B cells. (B) In vitro expanded B cell showed improved proliferation activity compared to naïve B cells. Cell proliferation was analyzed by flow cytometry using propidium iodide exclusion. (C) STRO-001 showed more potent cell killing of proliferating B cells (EC50 = 0.49 nM) than naïve B cells (EC50 = 11 nM).